Displaying drugs 2276 - 2300 of 2971 in total
MVA-BN-brachyury-TRICOM vaccine
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1...
Investigational
Matched Description: … transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory ... recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human ... molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules …
Stamulumab
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Matched Description: … MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases …
Pelitinib
Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.
Investigational
Matched Description: … EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor …
Mometasone
Mometasone is a corticosteroid not currently used in medical products. Mometasone furoate however, is still in use.
Experimental
Sennosides
Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label] and empty the large intestine before surgery. The medication is taken by mouth or via the rectum[FDA Label]. It typically begins working in minutes when given by rectum and within twelve hours when given...
Experimental
Matched Description: … laxative medication, has recently proven effective in inhibiting the ribonuclease H (RNase H) activity of human …
Matched Mixtures name: … FIBROLAX COMPLEX ... FIBROLAX COMPLEX ... FIBROLAX COMPLEX …
Matched Categories: … Complex Mixtures …
Matched Mixtures name: … FIBROLAX COMPLEX ... FIBROLAX COMPLEX ... FIBROLAX COMPLEX …
Matched Categories: … Complex Mixtures …
N4-Hydroxycytidine
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Description: … in mice and human airway epithelial cells. ... [A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable. ... A193023] It has shown antiviral activity against Venezuelan equine encephalitis virus,[A193008] and the human …
1D09C3
1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include...
Investigational
Matched Description: … 1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex ... The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies …
Voglibose
Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.
Investigational
Xentuzumab
Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
Investigational
Matched Description: … clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor …
BEA-17
BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. It is under investigation for the treatment of glioblastoma.
Investigational
Matched Description: … BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. …
ST-36
ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.
Investigational
Matched Description: … ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. …
HTPEP-001
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Matched Description: … HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta …
AME-527
AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.
Investigational
Matched Description: … AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity …
Linseed oil
Linseed oil is a rich source of α-Linolenic acid extracted from the dried, ripened seeds of the flax plant Linum usitatissimum. Other fatty acids contained in linseed oil include palmitic acid, stearic acid, oleic acid and linolenic acid. Linseed oil is particularly susceptible to polymerization reactions upon exposure to oxygen...
Investigational
Matched Mixtures name: … Herbs of Gold B Complex Plus Softgel …
Matched Categories: … Complex Mixtures …
Matched Categories: … Complex Mixtures …
SAR-439459
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Investigational
Matched Description: … SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. …
Amolimogene
Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.
Investigational
Matched Description: … is an investigational therapeutic designed to specifically augment the body's defensive response to human …
Custirsen
Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in...
Investigational
Dovitinib
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I...
Investigational
H3B-8800
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Tanezumab
Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
Investigational
Matched Categories: … Receptor, Nerve Growth Factor, antagonists & inhibitors …
BBM-H901
BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.
Investigational
Matched Description: … BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor …
PT-2385
PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Investigational
Matched Description: … PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau …
Tulisokibart
PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Matched Description: … monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor …
CTCE-0214
CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.
Investigational
Matched Description: … CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule …
Displaying drugs 2276 - 2300 of 2971 in total